Cydan, NEA’s Orphan Drug Accelerator, Targets Sickle Cell With Startup Imara | Xconomy

on
 
Cydan, NEA’s Orphan Drug Accelerator, Targets Sickle Cell With Startup Imara | Xconomy
Cydan, New Enterprise Associates’s orphan drug startup accelerator, has taken a look at around 600 assets since it was formed some three years ago. Sifting
XCONOMY.COM

Comments

Post a Comment